Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.

The Journal of physiology - 15 Jun 2017

Flenner Frederik, Geertz Birgit, Reischmann-Düsener Silke, Weinberger Florian, Eschenhagen Thomas, Carrier Lucie, Friedrich Felix W

Abstract excerpt

KEY POINTS: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac illness and can lead to diastolic dysfunction, sudden cardiac death and heart failure. Treatment of HCM patients is empirical and current pharmacological treatments are unable to stop disease progression or reverse hypertrophy. In this study, we tested if the non-dihydropyridine Ca2+ channel blocker diltiazem, which previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy, Hypertrophic
Share to Diastole

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Ventricles

Share to Isoproterenol

Share to Myocardial Contraction

Share to Myocardium

Share to Myocytes, Cardiac

Share to Sarcomeres

Source

Open in PubMed Open full text

Identifiers

PMID: 28090637
DOI: 10.1113/JP273769
PMCID: PMC5471503

Genes

MYBPC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.PMID 28090637Read ↗

Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.Semantic proximity Read ↗

Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.Semantic proximity Read ↗

Translational investigation of electrophysiology in hypertrophic cardiomyopathySemantic proximity Read ↗

Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model.Semantic proximity Read ↗

Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.Semantic proximity Read ↗

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.Semantic proximity Read ↗

Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathySemantic proximity Read ↗

Myosin inhibitor reverses hypertrophic cardiomyopathy in pediatric iPSC-cardiomyocytes to mirror variant correctionSemantic proximity Read ↗

[Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling].Semantic proximity Read ↗

Acute heart failure with cardiomyocyte atrophy induced in adult mice by ablation of cardiac myosin light chain kinase.Semantic proximity Read ↗

Contractile dysfunction in a mouse model expressing a heterozygous MYBPC3 mutation associated with hypertrophic cardiomyopathy.Semantic proximity Read ↗

Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.